Who's who

3 Houston innovators to know this week

This week's Houston innovators to know roundup includes Josh Pherigo of the Greater Houston Partnership, Brittany Barreto of FemTech Focus, and Ted Gutierrez of SecurityGate.io. Photos courtesy

Editor's note: Another Monday, another round of innovators to know in Houston as you start your week. This week's edition features a researcher who has crunched the numbers on Houston's tech specialties, a founder who's shining a spotlight on femtech, and an entrepreneur who's snagged a deal with Chevron.

Josh Pherigo, research director of data analytics at the Greater Houston Partnership

Josh Pherigo at GHP used data to look into what tech specialties are thriving in Houston — and what niches have shown promising growth. Photo via LinkedIn

When Josh Pherigo decided to look where venture capital money was going in Houston, he did so to investigate what potential industries had growth opportunities. He found that Houston has an opportunity to be a leader in clean tech — but it has some in-state competition.

Pherigo's study for the Greater Houston Partnership found that there was a cleantech war emerging between Austin and Houston. While Houston's ecosystem has a greater presence of cleantech startups, Austin cleantech is still bringing in more VC investments. However, in Houston, between new corporate incubators and Greentown Labs entering Houston, the city is creating a lot of infrastructure for this industry.

"It's going to be interesting over the next few years to see how Houston can position itself as the leader in Texas for this, because they are going to have a lot of competition from Austin," Pherigo says. Read more.

Brittany Barreto, founder of FemTech Focus

Brittany Barreto launched FemTech Focus to help call attention to women's health and wellness, as well as to help accelerate companies with tech solutions within the field. Photo courtesy of FemTech Focus

Brittany Barreto has conducted dozens of interviews with femtech entrepreneurs, and it's become abundantly clear that general accelerators aren't giving femtech companies the full picture.

"Femtech startups actually need a little bit of different advice — that's why I'm very bullish on creating a femtech accelerator," Barreto says. "In femtech, we have some unique barriers. If you just go to a general accelerator, they might not cover these issues, and you'll be blindsighted."

Barreto is now working on specified program with The Guild that's launching this month. Then, in 2021, she hopes to go live with a full program under her company, FemTech Focus. Read more.

Ted Gutierrez, founder and CEO of SecurityGate.io

Chevron has tapped SecurityGate.io's risk management cybersecurity platform. Photo courtesy of Security Gate

Last week, Ted Gutierrez announced that his company, SecurityGate.io scored a partnership with Chevron. The deal means that the energy giant will adopt SecurityGate's risk management platform for scaling operational technology cybersecurity.

"We're very excited to be working with Chevron as they replace manual, spreadsheet cybersecurity practices with scalable, digitized processes," says Ted Gutierrez, CEO at SecurityGate.io, in a press release. "Their risk management team has done amazing work and it's exciting to see where they're headed." Read more.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News